Remdesivir does not reduce mortality of covid-19 patients, says study

0
4


Antiviral remdesivir had little or no effect on patients’ hospital stay or survival chances, study found

The medicine remdesivir, from Gilead Sciences, had little or almost no effect on hospitalization times or chances of survival for patients in the covid-19, concluded a study by the World Health Organization (WHO).

Antiviral medication, one of the first to be used as a treatment for covid-19, was one of the drugs used to treat US President Donald Trump after his coronavirus infection.

The results are from the WHO “Solidarity” study, which evaluated the effects of four treatments with medications that included remdesivir, hydroxychloroquine, and the combination of lopinavir / ritonavir and interferon (used to treat HIV) in 11,266 patients adults in more than 30 countries.

Subscribe and have the best content of your day, perhaps the only one you need.

digital exam

R $ 15.90 / month

  • Access wherever and whenever you want.
  • Unlimited access to exclusive content on macroeconomics, markets, careers, entrepreneurship, technology and finance.

digital + printed exam

R $ 44.90 / month

  • Access wherever and whenever you want
  • Unlimited access to exclusive content on macroeconomics, markets, careers, entrepreneurship, technology and finance.
  • Biweekly print edition.
  • Free shipping

3979968

LEAVE A REPLY

Please enter your comment!
Please enter your name here